Literature DB >> 23323803

Patterns of use of insulin-sensitizing agents among diabetic, borderline diabetic and non-diabetic women in the National Health and Nutrition Examination Surveys.

Hind Beydoun1, Vijaya Kancherla, Laurel Stadtmauer, May Beydoun.   

Abstract

The purpose of this cross-sectional study based on the 2001-2006 National Health and Nutrition Examination Survey is to examine demographic, socioeconomic, lifestyle and reproductive characteristics that may distinguish users and non-users of insulin sensitizing agents among the US diabetic, borderline diabetic and non-diabetic women. Use of insulin-sensitizing agents was evaluated among 19,579 (3882 diabetic, 387 borderline diabetic and 15,310 non-diabetic) women. Overall, 2% of women in the study sample were users of insulin-sensitizers, including metformin, rosiglitazone and pioglitazone. Multivariate logistic regression models were constructed for predictors of insulin-sensitizer use according to diabetic status. In the overall sample, being younger or diabetic were the only factors associated with an increased odds of using insulin-sensitizing agents, after adjustment of confounders. Among diabetics, use of insulin-sensitizing agents was inversely related to age, but not other factors in the multivariable model. Among borderline and non-diabetics, body mass index (BMI) was the only predictor that remained significantly associated with the use of insulin-sensitizing agents after controlling for confounders. In conclusion, the main predictors of insulin-sensitizer use are young age and diabetic status in all women, young age in diabetic women and high BMI in borderline and non-diabetic women.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23323803      PMCID: PMC3772626          DOI: 10.3109/09513590.2012.752457

Source DB:  PubMed          Journal:  Gynecol Endocrinol        ISSN: 0951-3590            Impact factor:   2.260


  25 in total

Review 1.  Troglitazone and related compounds: therapeutic potential beyond diabetes.

Authors:  T Fujiwara; H Horikoshi
Journal:  Life Sci       Date:  2000-10-06       Impact factor: 5.037

2.  Diet, obesity, and cardiovascular risk.

Authors:  Robert O Bonow; Robert H Eckel
Journal:  N Engl J Med       Date:  2003-05-22       Impact factor: 91.245

3.  Effect of metformin plus roziglitazone compared with metformin alone on glycaemic control in well-controlled Type 2 diabetes.

Authors:  M W Stewart; D T Cirkel; K Furuseth; J Donaldson; N Biswas; M G Starkie; C Phenekos; A Hamann
Journal:  Diabet Med       Date:  2006-10       Impact factor: 4.359

Review 4.  Should patients with polycystic ovary syndrome be treated with metformin? Benefits of insulin sensitizing drugs in polycystic ovary syndrome--beyond ovulation induction.

Authors:  Laurel A Stadtmauer; Benjamin C Wong; Sergio Oehninger
Journal:  Hum Reprod       Date:  2002-12       Impact factor: 6.918

Review 5.  Metformin and troglitazone in the treatment of female infertility associated with polycystic ovarian syndrome.

Authors:  H Sangraula; K R Paudel; M Sharma
Journal:  JNMA J Nepal Med Assoc       Date:  2009 Oct-Dec       Impact factor: 0.406

Review 6.  Cardiovascular effects of insulin sensitizers in diabetes.

Authors:  Ali Jawa; Vivian Fonseca
Journal:  Curr Opin Investig Drugs       Date:  2006-09

Review 7.  [A case of lactic acidosis caused by buformin in an oldest elderly diabetic patient].

Authors:  Takahiko Matsuura; Mariko Miyao; Yuzo Mizuno
Journal:  Nihon Ronen Igakkai Zasshi       Date:  2005-03

Review 8.  Metformin: a new oral biguanide.

Authors:  R K Campbell; J R White; B A Saulie
Journal:  Clin Ther       Date:  1996 May-Jun       Impact factor: 3.393

Review 9.  Phenformin and lactic acidosis: a case report and review.

Authors:  S C Kwong; J Brubacher
Journal:  J Emerg Med       Date:  1998 Nov-Dec       Impact factor: 1.484

Review 10.  Troglitazone: the discovery and development of a novel therapy for the treatment of Type 2 diabetes mellitus.

Authors:  Janice C Parker
Journal:  Adv Drug Deliv Rev       Date:  2002-11-05       Impact factor: 15.470

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.